trastuzumab deruxtecan biosimilar / Samsung - LARVOL DELTA

…Samsung Launches Development of $10 Billion-Per-Year ADC Cancer Drug… Unprecedented Even in US and Europe (The Asia Business Daily) - "According to the bio industry on November 21, Samsung Bioepis's Enhertu biosimilar project has entered the early development stage ahead of preclinical trials....The company's announced plan to submit an ADC IND (investigational new drug application) in 2025 and enter Phase 1 clinical trials in 2026 pertains to its new drug development schedule, while the biosimilar business-its cash cow-is simultaneously advancing the Enhertu project."

New P1 trial • Oncology